Related Experiment Video
Updated: Jul 16, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Response to benralizumab in patients with severe eosinophilic asthma
Jorge Isaac Velasco-Santos1, Francisco Javier Núñez-Martínez2, Brian Humberto Martínez-Sánchez3
1Instituto Mexicano del Seguro Social, Hospital General Regional No. 13, Departamento de Medicina Interna. Tuxtla Gutiérrez, Chiapas, México.
Background:
Severe asthma represents a significant public health challenge, and monoclonal antibodies such as benralizumab represent an effective therapeutic option for achieving disease control.
Objective:
To evaluate the effectiveness of benralizumab in patients with severe eosinophilic asthma by assessing changes in fractional exhaled nitric oxide (FeNO), peripheral blood eosinophils, symptom control, forced expiratory volume in 1 second (FEV1), and exacerbation rates six months after treatment initiation.
Materials And Methods:
A prospective observational study was conducted in 11 patients with severe uncontrolled eosinophilic asthma. Clinical outcomes (ACT), quality of life (mini-AQLQ), FEV1, exacerbations, and biomarkers of blood eosinophils and FeNO were assessed at baseline and six months.
Results:
After six months of benralizumab therapy, > 90% of patients showed significant improvement in quality of life (mini-AQLQ, p < 0.05), and 72.7% achieved better asthma control (ACT, p < 0.05). Exacerbations decreased by 66.9% (p < 0.05). Blood eosinophils decreased by 97.5% (p < 0.05), FeNO by 57% (p < 0.05), and FEV1 increased by 27.7% (p < 0.05).
Conclusions:
Benralizumab demonstrated significant clinical and inflammatory benefits in this cohort, improving biomarkers, lung function, exacerbation rates, and patient-reported outcomes, supporting its effectiveness in real-world management of severe eosinophilic asthma.
Related Concept Videos
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Asthma I: Introduction
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma III: Clinical Manifestations